Celebrating 25 years Est 1999-2024
*Across 3 years $3395.52 only $1358.21
In a report released yesterday, John Hester from Bell Potter maintained a Buy rating on Paradigm Biopharmaceuticals Ltd. (PBIGF - Research...
The company's shares closed last Thursday at $0.96, close to its 52-week low of $0.96. According to TipRanks.com, Wilkie is a 4-star analyst with...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.